Ambrisentan

This medication produced by Lucius Pharmaceuticals, as a treatment for pulmonary arterial hypertension, has clear clinical efficacy data to support it, and its dosage form design facilitates long-term standardized medication use for patients.

Overview of Key Information About This Medication

Active Ingredient

The main active ingredient is ambrisentan, which belongs to the class of endothelin receptor antagonists.

Target Population

It is indicated for adult patients with pulmonary arterial hypertension (PAH), especially those with WHO Functional Class II–III.

Dosage and Administration

The recommended starting dose is 5 mg once daily, which can be taken with or without food. After 4 weeks, the dose may be considered for an increase to 10 mg once daily.Reference Article: Dosage and Administration of Ambrisentan

Use in Specific Populations

It is contraindicated in pregnant women. Women of childbearing potential must use effective contraception.

Elderly patients have a higher risk of peripheral edema.

Use is not recommended in patients with moderate to severe hepatic impairment.

Drug Overdose

Overdose may present with symptoms such as headache, dizziness, and hypotension. Symptomatic treatment is required, and vital signs should be monitored.

Storage

The medication should be stored in its original packaging at room temperature, protected from moisture and light.

Pharmacokinetics

After oral administration, the peak plasma concentration is reached approximately 2 hours. The half-life is about 15 hours, and the drug is mainly eliminated via non-renal pathways.

FDA，2025.04